Figure 1.
Time on study by t(11;14) status and response to treatment. Patients in the non-t(11;14) group were identified either as not having t(11;14) or having undetermined cytogenetics. Venetoclax monotherapy is shown in red for patients with t(11;14) and in blue for patients in the non-t(11;14) group. Seventeen patients who progressed during monotherapy elected to receive venetoclax plus dexamethasone (shown in green) and stayed on study. Clinical responses are also shown on the left axis. *Patient discontinued with no response data. #Patient discontinuation was related to disease progression. CR, complete response; MR, minimal response; PD, progressive disease; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.